Expertise in
2
conditions

Gil Sela-Bar

8 Ha'Aliyah Street, 
Haifa, HA, IL 
Expertise in
2
conditions
8 Ha'Aliyah Street, 
Haifa, HA, IL 
OverviewLocationsClinical Research

Overview

Gil Sela-Bar practices in Haifa, Israel. Mr. Sela-Bar is highly rated in 2 conditions, according to our data. His top areas of expertise are Melanoma, Magnesium Deficiency, Kaposi Sarcoma, Embolectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 164 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

8 Ha'Aliyah Street, Haifa, HA 35254, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other
Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Docetaxel, Pembrolizumab, FOLFIRI
Study Phase: Phase 1/Phase 2
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

164 Total Publications

Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications.
Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications.
Journal: Cells
Published: August 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sela-Bar's expertise for a condition
ConditionClose
      View All 30 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile